Corporate Update Presentation

/in , , /by

Botanix Pharmaceuticals has released a corporate presentation to the ASX this morning, which is being shared with investors as part of meetings over the course of the next week.

Key highlights include:

  • Successful launch of BTX 1702 rosacea clinical study, with recruitment well underway
  • Design of the BTX 1204A pilot study of canines with atopic dermatitis, which is about to commence 
  • Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients
  • Reviewing new opportunities to leverage the unique properties of our Permetrex™ technology platform in dermatology 

Our Company remains in a strong financial position, holding a cash balance of A$21.56m at 30 June 2021, and is progressing strategically forward to deliver these core programs.

Read Presentation and ASX Release here.

Botanix FY21 Annual Report

/in , /by

Botanix (ASX:BOT) has today published its its Annual Report for the 2020-2021 Financial Year (FY21)

Key highlights from this financial year include:

  • Successful completion of BTX 1801 antimicrobial  Phase 2a  clinical  study, showing two different BTX 1801 formulations were safe, well tolerated and successful at eradicating Staphylococcus Aureus.
  • BTX 1702 rosacea clinical study was successfully launched in Australia & New Zealand and is actively recruiting.
  • Positive results achieved from the BTX 1204A pilot study of canines with atopic dermatitis, with a larger proof of concept canine study ready to kick off.
  • Expansion of the Management team  in  the  US  to  drive  clinical  and  commercial activities across the antimicrobial and dermatology programs.
  • Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients is progressing well and is positioned to validate synthetic CBD as a novel new antimicrobial.

Click here to read the report.

Research Report by Euroz Hartleys

/in , /by

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has initiated coverage on Botanix as we lead into an exciting 12 months of clinical studies and corporate activities.

This report reinforces our belief that Botanix has assembled the right people, technology and research strategies to advance our assets, and to deliver positive results for our shareholders and the patients we exist to serve.

Read the full report.

/in , , /by

Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.

Click here to view the report.